

**laronidase (Aldurazyme)**

**(No. 100/04)**

**Genzyme Therapeutics**

**Summary of Recommendation**

12 July 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**Advice:** following a full submission.

Laronidase is not recommended for use within NHS Scotland for the treatment of mucopolysaccharidosis I. Laronidase was approved by the EMEA under exceptional circumstances and has been granted orphan drug status. The evidence of its efficacy is therefore limited. No information is presented in the submission to support the therapy being cost effective and therefore the economic case is not demonstrated.

The licence holder has indicated their decision to resubmit.

Professor David Webb  
Deputy Chairman